Bambang Pujo Semedi, Nadya Noor Ramadhania, Betty Agustina Tambunan, Siprianus Ugroseno Yudho Bintoro, Soedarsono Soedarsono, Cita Rosita Sigit Prakoeswa
{"title":"COVID-19重症、危重症患者恢复期血浆治疗延长ICU住院时间的研究","authors":"Bambang Pujo Semedi, Nadya Noor Ramadhania, Betty Agustina Tambunan, Siprianus Ugroseno Yudho Bintoro, Soedarsono Soedarsono, Cita Rosita Sigit Prakoeswa","doi":"10.1155/2022/1594342","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate its effects on ICU mortality, ICU length of stay (LoS), and improvement of oxygen support requirements.</p><p><strong>Methods: </strong>Data of all severe and critically-ill patients in our COVID-19 ICU was collected retrospectively between May and November 2020. We dichotomized the variables and compared outcome data of 48 patients, who received convalescent plasma to 131 patients, receiving standard of care. Data were analyzed using multiple logistic regression to make prediction models of mortality, length of stay, and oxygen support device requirement.</p><p><strong>Result: </strong>Overall mortality rate in our COVID-19 ICU was 55.3%, with a median overall length of stay of 8 (4-11) days. Less patients that received convalescent plasma presented with the need for mechanical ventilation on ICU admission (<i>p</i> < 0.001), but with comparable PaO<sub>2</sub> to FiO<sub>2</sub> (P/F) ratio (<i>p</i>=0.95). Factors that confounded mortality were obesity (aOR = 14.1; 95% CI (1.25, 166.7); <i>p</i>=0.032), mechanical ventilation (aOR = 333; 95% CI (4.5,1,000); <i>p</i> < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (aOR = 7.32; 95% CI (1.82, 29.4); <i>p</i>=0.005), and lower P/F ratio (aOR = 7.70; 95% CI (2.04, 29.4); <i>p</i>=0.003). ICU LoS was longer in patients, who had prior history of hypertension (aOR = 2.14; 95% CI (1.05, 4.35); <i>p</i>=0.036) and received convalescent plasma (aOR = 3.88; 95% CI (1.77, 8.05); <i>p</i> < 0.001). Deceased patients, who received convalescent plasma, stayed longer in the ICU with a mean length of stay of 12.87 ± 5.7 days versus 8.13 ± 4.8 days with a significant difference (<i>U</i> = 434; <i>p</i> < 0.000). The chance of improved oxygen support requirements was lower in obese patients (aOR = 9.18; 95%CI (2.0, 42.1); <i>p</i> < 0.004), mechanically ventilated patients (aOR = 13.15; 95% CI (3.75, 46.09); <i>p</i> < 0.001), patients with higher NLR (aOR = 2.5; 95% CI (1.07, 5.85); <i>p</i>=0.034), and lower P/F ratio (aOR = 2.76; 95% CI (1.1, 6.91); <i>p</i>=0.031).</p><p><strong>Conclusion: </strong>The length of stay of patients in the convalescent plasma group was significantly longer than the control group. There was no effect of convalescent plasma in ICU mortality and no improvement was observed in terms of oxygen support requirements.</p>","PeriodicalId":46583,"journal":{"name":"Critical Care Research and Practice","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473920/pdf/","citationCount":"2","resultStr":"{\"title\":\"Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy.\",\"authors\":\"Bambang Pujo Semedi, Nadya Noor Ramadhania, Betty Agustina Tambunan, Siprianus Ugroseno Yudho Bintoro, Soedarsono Soedarsono, Cita Rosita Sigit Prakoeswa\",\"doi\":\"10.1155/2022/1594342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate its effects on ICU mortality, ICU length of stay (LoS), and improvement of oxygen support requirements.</p><p><strong>Methods: </strong>Data of all severe and critically-ill patients in our COVID-19 ICU was collected retrospectively between May and November 2020. We dichotomized the variables and compared outcome data of 48 patients, who received convalescent plasma to 131 patients, receiving standard of care. Data were analyzed using multiple logistic regression to make prediction models of mortality, length of stay, and oxygen support device requirement.</p><p><strong>Result: </strong>Overall mortality rate in our COVID-19 ICU was 55.3%, with a median overall length of stay of 8 (4-11) days. Less patients that received convalescent plasma presented with the need for mechanical ventilation on ICU admission (<i>p</i> < 0.001), but with comparable PaO<sub>2</sub> to FiO<sub>2</sub> (P/F) ratio (<i>p</i>=0.95). Factors that confounded mortality were obesity (aOR = 14.1; 95% CI (1.25, 166.7); <i>p</i>=0.032), mechanical ventilation (aOR = 333; 95% CI (4.5,1,000); <i>p</i> < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (aOR = 7.32; 95% CI (1.82, 29.4); <i>p</i>=0.005), and lower P/F ratio (aOR = 7.70; 95% CI (2.04, 29.4); <i>p</i>=0.003). ICU LoS was longer in patients, who had prior history of hypertension (aOR = 2.14; 95% CI (1.05, 4.35); <i>p</i>=0.036) and received convalescent plasma (aOR = 3.88; 95% CI (1.77, 8.05); <i>p</i> < 0.001). Deceased patients, who received convalescent plasma, stayed longer in the ICU with a mean length of stay of 12.87 ± 5.7 days versus 8.13 ± 4.8 days with a significant difference (<i>U</i> = 434; <i>p</i> < 0.000). The chance of improved oxygen support requirements was lower in obese patients (aOR = 9.18; 95%CI (2.0, 42.1); <i>p</i> < 0.004), mechanically ventilated patients (aOR = 13.15; 95% CI (3.75, 46.09); <i>p</i> < 0.001), patients with higher NLR (aOR = 2.5; 95% CI (1.07, 5.85); <i>p</i>=0.034), and lower P/F ratio (aOR = 2.76; 95% CI (1.1, 6.91); <i>p</i>=0.031).</p><p><strong>Conclusion: </strong>The length of stay of patients in the convalescent plasma group was significantly longer than the control group. There was no effect of convalescent plasma in ICU mortality and no improvement was observed in terms of oxygen support requirements.</p>\",\"PeriodicalId\":46583,\"journal\":{\"name\":\"Critical Care Research and Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473920/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Care Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/1594342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/1594342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 2
摘要
背景:对COVID-19重症和危重症患者的恢复期血浆给药已被证明不能改善患者的预后,但由于其高可用性和安全性,在资源有限的国家仍被广泛使用。本研究旨在探讨其对ICU死亡率、ICU住院时间(LoS)和改善氧支持需求的影响。方法:回顾性收集2020年5月至11月我院COVID-19重症监护病房所有重症和危重症患者的资料。我们对变量进行了二分类,并比较了48例接受恢复期血浆治疗的患者和131例接受标准治疗的患者的结局数据。采用多元logistic回归对数据进行分析,建立死亡率、住院时间和供氧设备需求的预测模型。结果:新冠肺炎ICU患者总死亡率为55.3%,中位总住院时间为8(4 ~ 11)天。接受恢复期血浆治疗的患者入院时需要机械通气的患者较少(p < 0.001),但PaO2 / FiO2 (p /F)比值相当(p=0.95)。混淆死亡率的因素是肥胖(aOR = 14.1;95% ci (1.25, 166.7);p=0.032)、机械通气(aOR = 333;95% ci (4.5, 1000);p < 0.001),中性粒细胞与淋巴细胞比值(NLR)较高(aOR = 7.32;95% ci (1.82, 29.4);p=0.005), p /F比较低(aOR = 7.70;95% ci (2.04, 29.4);p = 0.003)。既往有高血压病史的患者ICU LoS较长(aOR = 2.14;95% ci (1.05, 4.35);p=0.036),接受恢复期血浆治疗(aOR = 3.88;95% ci (1.77, 8.05);P < 0.001)。接受恢复期血浆治疗的死亡患者在ICU的平均住院时间为12.87±5.7天,而接受恢复期血浆治疗的死亡患者在ICU的平均住院时间为8.13±4.8天,差异有统计学意义(U = 434;P < 0.000)。肥胖患者改善氧支持需求的机会较低(aOR = 9.18;95%ci (2.0, 42.1);p < 0.004),机械通气患者(aOR = 13.15;95% ci (3.75, 46.09);p < 0.001), NLR较高的患者(aOR = 2.5;95% ci (1.07, 5.85);p=0.034), p /F比较低(aOR = 2.76;95% ci (1.1, 6.91);p = 0.031)。结论:恢复期血浆组患者住院时间明显长于对照组。恢复期血浆对ICU死亡率没有影响,在氧支持需求方面也没有改善。
Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy.
Background: Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate its effects on ICU mortality, ICU length of stay (LoS), and improvement of oxygen support requirements.
Methods: Data of all severe and critically-ill patients in our COVID-19 ICU was collected retrospectively between May and November 2020. We dichotomized the variables and compared outcome data of 48 patients, who received convalescent plasma to 131 patients, receiving standard of care. Data were analyzed using multiple logistic regression to make prediction models of mortality, length of stay, and oxygen support device requirement.
Result: Overall mortality rate in our COVID-19 ICU was 55.3%, with a median overall length of stay of 8 (4-11) days. Less patients that received convalescent plasma presented with the need for mechanical ventilation on ICU admission (p < 0.001), but with comparable PaO2 to FiO2 (P/F) ratio (p=0.95). Factors that confounded mortality were obesity (aOR = 14.1; 95% CI (1.25, 166.7); p=0.032), mechanical ventilation (aOR = 333; 95% CI (4.5,1,000); p < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (aOR = 7.32; 95% CI (1.82, 29.4); p=0.005), and lower P/F ratio (aOR = 7.70; 95% CI (2.04, 29.4); p=0.003). ICU LoS was longer in patients, who had prior history of hypertension (aOR = 2.14; 95% CI (1.05, 4.35); p=0.036) and received convalescent plasma (aOR = 3.88; 95% CI (1.77, 8.05); p < 0.001). Deceased patients, who received convalescent plasma, stayed longer in the ICU with a mean length of stay of 12.87 ± 5.7 days versus 8.13 ± 4.8 days with a significant difference (U = 434; p < 0.000). The chance of improved oxygen support requirements was lower in obese patients (aOR = 9.18; 95%CI (2.0, 42.1); p < 0.004), mechanically ventilated patients (aOR = 13.15; 95% CI (3.75, 46.09); p < 0.001), patients with higher NLR (aOR = 2.5; 95% CI (1.07, 5.85); p=0.034), and lower P/F ratio (aOR = 2.76; 95% CI (1.1, 6.91); p=0.031).
Conclusion: The length of stay of patients in the convalescent plasma group was significantly longer than the control group. There was no effect of convalescent plasma in ICU mortality and no improvement was observed in terms of oxygen support requirements.